DiscoverX to Highlight Capabilities of BioMAP® Platform for Investigative Toxicology and Safety Assessment at Society of Toxicology Meeting

Release date: 3/19/2014

Activities Include a Complimentary Workshop on Analysis of Failed Pharmaceutical Compounds Profiled in Primary Human Cell Systems Using BioMAP<sup>&reg;</sup>

<strong>FREMONT, CA (March 20, 2014):</strong> &nbsp;DiscoveRx Corporation, through its wholly owned division BioSeek, today announced plans to showcase capabilities of the company&rsquo;s BioMAP<sup>&reg; </sup>Platform of Primary Human Cell Systems for investigative toxicology and the safety assessment of drugs and biologics, chemicals, materials and other substances at the 53<sup>rd</sup> Annual Meeting of the Society of Toxicology (SOT), to be held March 23-27 in Phoenix, Arizona.<br /> &nbsp;<br /> In addition to scientific poster presentations by BioSeek and its collaborators during the conference, the company will sponsor a hosted workshop entitled &ldquo;Analysis of Failed Pharmaceutical Compounds in Primary Human Cell Systems.&rdquo; This event, moderated by Ellen Berg, Ph.D., Scientific Director of BioSeek, aims to bring together stakeholders from academia, government and industry to discuss the analysis of data on failed pharmaceutical compounds that have been profiled in the BioMAP<sup>&reg;</sup> platform of primary human co-culture assays as part of the U.S. Environmental Protection Agency&rsquo;s ToxCast<sup>&reg;</sup> program. BioSeek has collaborated with EPA since 2007 to screen a wide range of drugs, chemicals and other substances to predict chemical toxicities and potential drug adverse effects as part of ToxCast<sup>&reg;</sup>. &ldquo;Results gained through BioMAP<sup>&reg; </sup>profiling could have avoided the need for many expensive animal trials, thus saving much time and money in the drug discovery process,&rdquo; added Dr. Berg.<br /> &nbsp;<br /> &ldquo;The BioMAP<sup>&reg;</sup> platform was designed to capture clinically relevant profiles of therapeutics, chemicals and other substances that are uniquely informative and predictive of compound safety and bioactivity in the context of human biology,&rdquo; said Dr. Berg. &nbsp;&ldquo;The information gained through BioMAP<sup>&reg;</sup> profiling not only drives phenotypic discovery, but also the selection and development of safer drugs and biologics as well as chemicals and new materials for consumer products and agribusiness&rdquo;<br /> <strong>Workshop: <em>Analysis of Failed Pharmaceutical Compounds in Primary Human Cell Systems</em></strong><br /> March 25, 12:15 &ndash; 1:15 pm, Room 101C<br /> Space is limited. Please reserve a place <a href="http://marketing.discoverx.com/acton/fs/blocks/showLandingPage/a/5886/p/p-00b4/t/page/fm/0/r/l-ctx:1/s/l-ctx">via our website</a><br /> &nbsp;<br /> <strong>Scientific Posters &ndash; </strong><br /> &nbsp;<br /> <strong>March 26</strong><br /> <ul> <li> <em>&ldquo;Understanding Mechanisms of Drug-Induced Liver Injury Using Primary Human Cell and Co-Culture Systems&rdquo;</em></li> </ul> <div style="margin-left: 20px;"> Pfizer/ DiscoveRx/ BioSeek Abstract 1647/ Poster Board 340/ CC Exhibit Hall<br /> 9:00 AM to 12:30 PM&nbsp;<br /> &nbsp;</div> <strong>March 27</strong> <ul> <li> <em>&ldquo;Predictive Models for Mechanism-of-Action Classification of Chemicals&rdquo;</em></li> </ul> <div style="margin-left: 20px;"> DiscoveRx Corp./BioSeek, Inc.<br /> Abstract 2273w, Poster Board 478/ CC Hall 1<br /> 8:30 AM to 12:00 PM</div> &nbsp;<br /> <strong>Posters by DiscoveRx/Bioseek Partners Employing BioMAP Data</strong> <ul> <li> <em>&ldquo;Predicting Toxic and Therapeutic Mechanisms of the ToxCast Chemical Library by Phenotypic Screening&rdquo;</em>U.S. Environmental Protection Agency/ DiscoveRx/BioSeek</li> </ul> <div style="margin-left: 20px;"> Abstract 2273v/ Poster Board 477/ CC Hall 1<br /> 8:30 AM to 12:00 PM</div> &nbsp;<br /> <ul> <li> <em>&ldquo;In Vitro BioActivity in ToxCast Assays for Fruit and Vegetable Extracts&rdquo;</em></li> </ul> <div style="margin-left: 20px;"> The Hamner Institutes for Health Sciences/ DiscoveRx/ BioSeek/USEPA<br /> Abstract 2250/ Poster Board 416/ CC Hall1<br /> 8:30 AM to 12:00 PM</div> &nbsp;<br /> <strong>DiscoveRx/BioSeek at ToxExpo Exhibition</strong><br /> DiscoveRx/BioSeek personnel including Dr. Berg will also be available to discuss BioMAP<sup>&reg;</sup> Systems and its use in investigative toxicology and phenotypic drug discovery and development during the SOT ToxExpo.&nbsp; Please come meet us at the DiscoveRx/BioSeek booth, #1555.

<strong>About BioMAP Systems</strong><br /> <br /> BioMAP&reg; Systems incorporate predictive primary human cell-based disease models that generate uniquely informative activity profiles of each potential drug, assisting in the selection and development of new drug candidates. For more information on BioMAP drug discovery services, visit <a href="http://www.biomapsystems.com">www.biomapsystems.com</a><br /> <br /> <strong>About DiscoveRx Corporation</strong><br /> Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, CA., San Francisco, CA.&nbsp; and Birmingham, England. DiscoveRx is a leading provider of next generation proprietary platforms for both target-based and phenotypic based drug discovery.&nbsp; The company holds extensive intellectual property for its core technology platforms 1) PathHunter&reg;, HitHunter&reg; and&nbsp; InCELL Hunter&trade;: &beta;-galactosidase based enzyme fragment complementation, 2) KINOME<em>scan</em>&reg; : <em>in vitro </em>binding assay platform and 3) BioMAP: A three part drug discovery solution consisting of BioMAP system, proprietary database, and predictive analytics tools. Utilizing these proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of over 1000 target based and primary cell based assay solutions for Oncology, Metabolic Disease, Inflammation, CNS and Cardiovascular drug discovery research.&nbsp; Many of DiscoveRx&rsquo;s innovative solutions have been widely adopted in pharmaceutical, biotechnology and academic laboratories worldwide. For more information, visit <a href="http://www.discoverx.com">www.discoverx.com</a>.<br /> <br /> <br /> <strong>Media Contact</strong><br /> DiscoveRx Corporation<br /> Sailaja Kuchibhatla<br /> Sr. VP Business Development<br /> 42501 Albrae Street, Fremont, CA 94538<br /> tel | 510.979.1415 x104<br /> <a href="mailto:skuchibhatla@discoverx.com">skuchibhatla@discoverx.com</a><br /> <a href="http://www.discoverx.com">www.discoverx.com</a>